Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06541704 · ClinicalTrials.gov registry record · Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
A Phase 3 study of Age-related Macular Degeneration (AMD) and Geographic Atrophy (GA), sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 975
- Enrollment target
- 20
- Study locations
NCT06541704 is a Phase 3 study of Age-related Macular Degeneration (AMD) and Geographic Atrophy (GA) that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 975 participants, below the 101,783-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT06541704, a Phase 3 study of Age-related Macular Degeneration (AMD) and Geographic Atrophy (GA), is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 975 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting central vision (what one sees straight ahead). The purpose of this study is to evaluate the progression rate of Geographic Atrophy in eyes of patients treated with cemdisiran alone or in combination with pozelimab compared to those treated with placebo. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug(s) * How much study drug(s) are in the blood at different times * Whether the body makes antibodies against the study drug(s) (which could make the study drug(s) less effective or could lead to side effects)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pozelimab
- DRUG Cemdisiran
Study Locations (20)
California
- Retina Vitreous Associates Medical Group - Beverly Hills
- Retina Specialists of Beverly Hills- Department of Ophthalmology - Beverly Hills
- The Retina Partners - Encino
- Eye Medical Center of Fresno - Fresno
- Retina Consultants of Orange County - Fullerton
- Salehi Retina Institute dba Retina Associates of Southern California - Huntington Beach
- University of California Irvine - Irvine
- University of California San Diego, Jacobs Retina Center - La Jolla
- South Coast Retina Center - Long Beach
- American Institute of Research - Los Angeles
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Retinal Consultants Medical Group Inc Modesto - Modesto
- Northern California Retina Vitreous Associates Medical Group, Inc. - Mountain View
Arizona
- Barnet Dulaney Perkins Eye Center-Ophthamalogy - Chandler
- Barnet Dulaney Perkins Eye Center - Phoenix
- Associated Retina Consultants - Phoenix
- Retinal Research Institute - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
- Retina Associates of Tuscan - Tucson
Arkansas
- Retina Partners of Northwest Arkansas, PLLC - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 975 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2032-05-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06541704
The ClinicalTrials.gov registry entry for NCT06541704 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 975 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 101,783-participant average among 7 other Age-related Macular Degeneration (AMD) trials with a reported enrollment target (99% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Age-related Macular Degeneration (AMD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06541704 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06541704 about?
NCT06541704 is a clinical study titled "A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy". This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye c...
What is the current status of trial NCT06541704?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 975 participants. The study started on 2024-10-30. Estimated completion is 2032-05-21.
What conditions does trial NCT06541704 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA).
What interventions are being tested in trial NCT06541704?
The interventions under investigation include: Placebo (DRUG), Pozelimab (DRUG), Cemdisiran (DRUG).
Who is sponsoring clinical trial NCT06541704?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06541704 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration (AMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
RECRUITING
-
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
RECRUITING · Phase 2
-
Active AMD Study to Improve Function in Veterans
RECRUITING · NA
-
Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (Komodo Health)
COMPLETED
-
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
COMPLETED
-
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.